About
Foundation Medicine is a leader in precision oncology, leveraging AI and genomic data to transform cancer care. Their flagship comprehensive genomic profiling (CGP) tests analyze hundreds of cancer-related genes from tumor tissue or circulating tumor DNA (ctDNA), delivering actionable insights for treatment decisions. The FoundationOne CDx is an FDA-approved companion diagnostic for solid tumors, while FoundationOne Liquid CDx offers a non-invasive blood-based alternative. FoundationOne RNA extends profiling with fusion detection, and FoundationOne Heme addresses blood cancers. Beyond clinical testing, Foundation Medicine provides extensive biopharma services spanning drug discovery, translational research, clinical development, and companion diagnostic development. Their platform integrates seamlessly with all major Electronic Medical Record (EMR) systems, streamlining clinical workflows. A robust Knowledge Center and Medical Education portal offer oncology professionals continuing education and expert resources. Patients benefit from financial assistance programs and easy-to-understand result guides. With a deep biomarker database and AI-driven analysis, Foundation Medicine empowers oncologists, researchers, and pharmaceutical companies to make more informed, data-driven decisions across the full cancer care continuum.
Key Features
- Comprehensive Genomic Profiling (CGP): Analyzes hundreds of cancer-related genes from tissue or blood samples to identify actionable mutations, fusions, and biomarkers for targeted therapy selection.
- Multi-Modal Test Portfolio: Includes FoundationOne CDx (solid tumors), Liquid CDx (ctDNA/blood-based), RNA (fusion detection), and Heme (hematologic malignancies) to cover a broad range of cancer types.
- EMR Integration: Seamlessly integrates with all major Electronic Medical Record systems, enabling efficient clinical workflow and direct delivery of genomic reports.
- Biopharma Partner Services: Supports drug developers with biomarker discovery, clinical trial design, companion diagnostic development, and commercialization services.
- Knowledge Center & Medical Education: Provides oncology professionals with expert-curated educational resources, publications, and continuing medical education on precision oncology topics.
Use Cases
- Oncologists ordering comprehensive genomic profiling for advanced cancer patients to identify targeted therapy options and immunotherapy biomarkers.
- Biopharma companies using genomic data for biomarker discovery and patient stratification in clinical drug development programs.
- Hospital systems integrating genomic profiling results directly into EMR workflows to streamline cancer care decision-making.
- Researchers accessing Foundation Medicine's genomic database and publications to advance precision oncology knowledge.
- Patients with advanced cancer seeking actionable genomic insights to discuss treatment options with their oncology team.
Pros
- FDA-Approved Companion Diagnostics: FoundationOne CDx and Liquid CDx are FDA-approved, ensuring regulatory confidence and reimbursement eligibility for clinical use.
- End-to-End Oncology Ecosystem: Covers the full spectrum from patient testing to biopharma drug development, making it a comprehensive platform for all stakeholders in cancer care.
- Seamless EMR Integration: Works with all major EMR platforms, reducing administrative burden and streamlining result delivery into existing clinical workflows.
- Extensive Biomarker Coverage: Profiles a wide range of clinically relevant biomarkers including TMB, MSI, PD-L1, and hundreds of gene alterations in a single test.
Cons
- High Cost: Comprehensive genomic profiling tests are expensive, and insurance coverage can vary, potentially creating access barriers for some patients.
- US-Centric Platform: The primary website and services are designed for US-based healthcare professionals and patients; international users are redirected to a separate portal.
- Requires Clinical Context: Results require interpretation by qualified oncologists or genomic counselors, making it unsuitable as a standalone consumer tool.
Frequently Asked Questions
What is Comprehensive Genomic Profiling (CGP)?
CGP is a type of molecular testing that analyzes hundreds of cancer-related genes simultaneously from a tumor or blood sample to identify mutations, fusions, and biomarkers that may inform targeted treatment decisions.
What Foundation Medicine tests are available?
Foundation Medicine offers FoundationOne CDx (solid tumors), FoundationOne Liquid CDx (blood-based ctDNA), FoundationOne RNA (fusion detection), and FoundationOne Heme (hematologic cancers).
Does insurance cover Foundation Medicine tests?
Coverage varies by insurer and plan. Foundation Medicine provides billing and reimbursement support, and financial assistance programs are available for eligible patients.
How can biopharma companies use Foundation Medicine services?
Biopharma partners can leverage Foundation Medicine's genomic data and expertise for biomarker discovery, clinical trial patient selection, companion diagnostic development, and post-market commercialization support.
How does Foundation Medicine integrate with electronic medical records?
Foundation Medicine integrates with all major EMR platforms, enabling direct delivery of genomic test reports and data transfers into clinical workflows without manual intervention.
